Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $1.7M fell 58.4% year over year, ahead of the -67.9% change in trailing-twelve-month other income / expenses. Over 3 fiscal years it compounded at -1.8% a year.
Context
- Other income / expenses amounted to 25.3% of revenue in FY2025, down 45.8 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -58.4% holds above the trailing-twelve-month pace of -67.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 7.82M USD
- Year-over-year change
- -51.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.82M | -51.3% |
| FY2024 | 2024-12-31 | 16.06M | +17.2% |
| FY2023 | 2023-12-31 | 13.71M | +66.0% |
| FY2022 | 2022-12-31 | 8.26M | +1508.7% |
| FY2021 | 2021-12-31 | (586K) | — |
Other Income / Expenses vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 other income / expenses of $5.44M is the 8th highest of the 11 companies compared; the peer median is $6.61M.
- Its year-over-year change of -67.9% is the 10th highest of 11, against a peer median of -35.4%.
- Other income / expenses amounts to 19.3% of revenue for FHTX, versus a peer median of 23.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.3M | -51.1% | -2.8% | 808.4% | |
| LTM Mar 2026 | $13.26M | -32.7% | +71.0% | 231.0% | |
| LTM Mar 2026 | $10.66M | -47.6% | +36.1% | 4.9% | |
| LTM Mar 2026 | $10.54M | -22.0% | — | 23.2% | |
| LTM Mar 2026 | $7.16M | +37.9% | +80.4% | 10.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $6.06M | +52.8% | — | — |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $5.23M | -38.1% | +119.1% | — |
| LTM Mar 2026 | $4.79M | +95.0% | +39.6% | — | |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| Peer median (excluding FHTX) | $6.61M | -35.4% | +37.8% | 23.2% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.